Should I try Enhertu or clinical trial for bone mets after Truqap?
Community Member
2 days agoOncotype score in 2013 was 7. In 2022, new tumor on top of breast implant. Metastasis to bone. 1st line, Ibrance plus fulvestrant. In 2025, cancer mutated toPIK3ca. Changed to truqap plus fulvestrant in Feb 25. Was NED in August 25. Just had petscan Feb26. Cancer back in illead bone in right and back upper pelvis. Considering Enhurtu or a clinical trial at Ohio State. Only God can led my decisions
Community Member
2 days agoThis treatment decision sounds incredibly challenging, especially after seeing such positive results previously. Both Enhertu and clinical trials can offer important options for HR+ HER2- metastatic breast cancer, and discussing the potential benefits and risks of each with your oncology team will help guide the best path forward for your specific situation. Many patients find it helpful to connect with others who have faced similar treatment decisions - this community is here to support you through this process.
New to the community?
Create an account to connect with others navigating cancer.
Related Questions
- What is targeted chemo for ER+ breast cancer with Oncotype 32?
- What is my cancer recurrence risk without aromatase inhibitors?
- "What should I expect after breast cancer surgery and before seeing my oncologist?"
- My Journey with Early-Stage Breast Cancer
- Is Oncotype DX score of 25 high risk after 5 radiation treatments?
- Should I choose chemotherapy for my early-stage breast cancer?
- Should I try Enhertu or clinical trial for bone mets after Truqap?
- Should I push for Signatera test despite oncologist's concerns about stage 1 cancer?
© 2026 Outcomes4Me Inc. All rights reserved.